Proroxan

Proroxan

Clinical data
Other names	Pyrroxane, Pirroksan
Legal status
Legal status	Rx in Russia
Identifiers
IUPAC name 1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-3-(3-phenylpyrrolidin-1-yl)propan-1-one
CAS Number	33743-96-3
PubChem CID	36303
UNII	T5WT3QN49G
KEGG	D05641
CompTox Dashboard (EPA)	DTXSID9046285
Chemical and physical data
Formula	C21H23NO3
Molar mass	337.419 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CN(CC1C2=CC=CC=C2)CCC(=O)C3=CC4=C(C=C3)OCCO4
InChI InChI=1S/C21H23NO3/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16/h1-7,14,18H,8-13,15H2 Key:GZIISXIDAZYOLI-UHFFFAOYSA-N

Proroxan (INN; also known as pyrroxane and pirroksan) is a pharmaceutical drug used as an antihypertensive and in the treatment of Ménière's disease, motion sickness, and allergic dermatitis.¹²

Proroxan is a non-selective alpha-blocker (α-adrenoreceptor antagonist).¹

Proroxan was developed in the 1970s at the Institute of Toxicology of the USSR Ministry of Health³ and today is primarily used in Russia. Though originally developed as an antihypertensive, its use can lead to a decrease in alcohol and drug consumption. Currently proroxan is used almost exclusively in psychiatry, narcology, and neurology.³